Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drugresistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at 10:00 ET NEW YORK, Sept. 12, 2024 /PRNewswire/ - Bright Minds Biosciences Inc. (NASD ...